Clinical TrialMay 27, 2026, 08:02 AM
Galectin Therapeutics' Belapectin Reduces Varices in MASH Cirrhosis (p=0.04)
AI Summary
Galectin Therapeutics announced positive new analyses from its global NAVIGATE trial of belapectin, presented at EASL 2026. The data showed belapectin 2 mg/kg significantly reduced new varices at 18 months (p=0.04) and improved liver stiffness in high-risk MASH cirrhosis patients. These results, including a TOP Poster designation, support belapectin's potential as a disease-modifying therapy by modulating fibrogenesis balance and reducing portal hypertension risk.
Key Highlights
- Belapectin 2 mg/kg demonstrated a statistically significant reduction in new varices at 18 months in MASH cirrhosis patients (p=0.04).
- Significantly fewer belapectin-treated patients experienced worsening liver stiffness (11.7% vs. 23.9%; p=0.03).
- A greater proportion of belapectin-treated patients improved to the no/low-risk Baveno category (p=0.0073).
- Data from the global NAVIGATE trial were presented at the European Association for the Study of the Liver (EASL) Congress 2026.
- A poster presentation on risk reduction in clinically significant portal hypertension was designated a TOP Poster at EASL 2026.
- Belapectin's impact on fibrosis modulation was reflected by favorable shifts in the Pro-C3/CTX-III ratio.
- These findings support belapectin's potential as a disease-modifying therapy in MASH cirrhosis.
Price Impact
More from GALT